Cantor Fitzgerald began coverage and issued rating, and Morgan Stanley upgraded price objective and rating for Silence Therapeutics.
1 report, 1 independent
Updated Wed 00:00
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Cantor Fitzgerald began coverage and issued rating, and Morgan Stanley upgraded price objective and rating for Silence Therapeutics.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Silence Therapeutics
UK business
Nothing else this week.
-
Cantor Fitzgerald
American financial services company
-
Morgan Stanley
U.S. investment bank
Related events
- Cantor Fitzgerald, Morgan Stanley, and Royal Bank of Canada issued price target updates for Elevance Health, Inc. on September 12, 2026.
- Cantor Fitzgerald raised its price target and rating for Supernus Pharmaceuticals, Inc. on September 2, 2026, and the company filed a disclosure with the SEC.
- Cantor Fitzgerald raised its price target and rating, while Bank of America adjusted its rating and price target, with MarketBeat aggregating the stock rating data.
- Cantor Fitzgerald initiated coverage citing a durable business model, and Morgan Stanley provided analyst commentary on Samsara.
- Cantor Fitzgerald reiterated an Overweight rating for aTyr Pharma on August 20, 2025.